Akero Therapeutics (AKRO) Prices 5.228M Share Common Offering at $36/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Chardan Capital Markets Starts Akero Therapeutics (AKRO) at Buy
July 7, 2020 4:10 AM EDTChardan Capital Markets initiates coverage on Akero Therapeutics (NASDAQ: AKRO) with a Buy rating and a price target of $79.00.
For an analyst ratings summary and ratings history on Akero Therapeutics click here. For more ratings news on Akero Therapeutics click here.
Shares of Akero Therapeutics closed at $34.96 yesterday.
... MoreAkero Therapeutics (AKRO) Announces Proposed 4.75M Common Share Offering
July 6, 2020 7:03 AM EDTAkero Therapeutics, Inc. (NASDAQ: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, announced today that it has commenced an underwritten public offering of 4,750,000 shares of its common... More
